Aptevo Therapeutics Inc. (NASDAQ:APVO) Shares Shorted: Short Interest Up 59.0% in September

Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Free Report) was the target of a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 187,942 shares, a growth of 59.0% from the August 31st total of 118,188 shares. Based on an average trading volume of 336,643 shares, the days-to-cover ratio is currently 0.6 days. Approximately 10.4% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research note on Friday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Get Aptevo Therapeutics alerts:

View Our Latest Research Report on Aptevo Therapeutics

Aptevo Therapeutics Stock Down 2.2%

Aptevo Therapeutics stock traded down $0.04 during midday trading on Wednesday, hitting $1.82. The company’s stock had a trading volume of 24,079 shares, compared to its average volume of 106,352. Aptevo Therapeutics has a 12 month low of $1.37 and a 12 month high of $35.64. The company has a market capitalization of $3.29 million, a PE ratio of -0.04 and a beta of 1.60. The stock’s 50-day moving average price is $2.80 and its 200-day moving average price is $4.02.

Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($5.31) earnings per share for the quarter, beating the consensus estimate of ($6.02) by $0.71. As a group, equities analysts anticipate that Aptevo Therapeutics will post -17.04 EPS for the current year.

Aptevo Therapeutics Company Profile

(Get Free Report)

Aptevo Therapeutics Inc (NASDAQ:APVO) is a biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s research programs are designed to engage the immune system and direct it against specific disease-related cells or targets.

Aptevo’s pipeline is based primarily on its ADAPTIR and ADAPTIR-FLEX platform technologies, which support the development of engineered, multispecific antibodies. These programs have included investigational candidates such as APVO436, an immune-cell engager being studied in hematologic malignancies, and other compounds aimed at treating solid tumors and blood cancers.

Featured Stories

• Five stocks we like better than Aptevo Therapeutics
• Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
• O’Reilly Automotive’s Stock Slump Hides a Stronger Business
• McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
• Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.